Acquisition And Pipeline Expansion Will Unlock Healthcare Potential

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

30 Apr 25

Updated

28 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

37.1%

7D

8.8%

Loading

1Y

37.1%

7D

8.8%

You can edit this narrative until Nov 29 9:05 PM. Then, changes will post as Updates.

Author's Valuation

US$1939.5% undervalued

AnalystConsensusTarget Fair Value

Shared on 28 Nov 25

CRMD: Q3 Sales Strength And New Buy Rating Will Drive Momentum Forward

Analysts have raised their price target for CorMedix to $14 from the previous level, citing stronger than expected Q3 sales and improved visibility into operational performance as key drivers of the updated outlook. Analyst Commentary Following the recent preliminary Q3 results, analysts have provided updated insights into CorMedix’s outlook, highlighting both encouraging signs and ongoing areas of caution for the company’s future performance.

Shared on 14 Nov 25

Fair value Decreased 6.86%

CRMD: Strong Q3 Sales Will Drive Renewed Uptrend Momentum

Analysts have lowered their price target for CorMedix from $20.40 to $19.00, citing a more moderate revenue growth outlook and adjusted profit expectations. This comes despite optimism about robust Q3 sales and operational improvements.

Shared on 04 Sep 25

Fair value Increased 2.00%

CorMedix’s consensus price target has edged up to $20.40, as analysts see greater revenue potential from DefenCath’s accelerating launch, expanded patient uptake, and supportive reimbursement dynamics, offsetting equity-related dilution concerns. Analyst Commentary The recent $85M equity offering extends CorMedix's cash runway but introduces dilution, prompting a reduced price target from previous levels based on valuation concerns.